MHLW Warns Use Of Chugai’s Pegasys In Patients With Interstitial Pneumonia
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare has ordered Chugai Pharmaceutical to change labeling for interferon drug Pegasys (peginterferon Alfa-2a) for hepatitis C. MHLW contraindicated the use of the drug on patients with history of interstitial pneumonia. The decision is based on a comparison to other drugs; a higher hepatitis recurrence rate was reported among Pegasys patients with a history of interstitial pneumonia. (Click here for more - Japanese language